^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

Excerpt:
...Patients with histologically or cytologically proven non-epidermoid, non-small cell lung cancer, non-EGFR (Epidermal Growth Factor Receptor)-mutated (or mutation test impracticable)....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

Excerpt:
...EGFR(epidermal growth factor receptor) mutations, ALK(anaplastic lymphoma kinase) gene fusion, etc.) could be included; 5....
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Phase II trial of Acteinib combined with Bevacizumab in the treatment of brain metastases from advanced EGFR mutation-positive lung adenocarcinoma

Excerpt:
...Patients with lung adenocarcinoma confirmed by histology or cytology and detected EGFR mutation; 4. ...
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy

Published date:
10/16/2023
Excerpt:
A total of 178 patients with EGFR-mutant lung adenocarcinoma and BM who received cerebral radiotherapy met the inclusion criteria for this retrospective study, including 70 patients in the bevacizumab treatment group and 108 in the non-bevacizumab group....Patients treated with bevacizumab after cerebral radiotherapy had a longer median OS than patients treated with bevacizumab before cerebral radiotherapy (59.4 months vs 33.7months, P=0.0198).
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

Published date:
06/28/2021
Excerpt:
A total of 30 patients with advanced lung adenocarcinoma and activating EGFR mutations concurrently received an EGFR-TKI and platinum-based doublet chemotherapy with or without bevacizumab….Of the 28 patients who had measurable lesions, the objective response rate and disease control rate were 71.4% and 96.4%, respectively (one patient achieved complete remission, 19 patients had a partial response and seven patients had stable disease).
Secondary therapy:
Chemotherapy + EGFR inhibitor
DOI:
10.1111/1759-7714.14057
Evidence Level:
Sensitive: C3 – Early Trials
Title:

MA12.08 - Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma

Published date:
01/12/2021
Excerpt:
We divided all the patients into two groups according to different subsequent regimens just after SCLC transformation. There were 12 in the etoposide/cisplatin or irinotecan/cisplatin chemotherapy group (EP/IP group) and 9 in the chemotherapy plus bevacizumab or EGFR-TKIs group (Combo group). The ORR was significantly higher in the Combo group than the EP/IP group (50% vs 25%, P=0.002)....Chemotherapy plus EGFR TKIs or bevacizumab could provide better efficacy than chemotherapy alone for SCLC-transformed EGFR-mutant patients with advanced lung adenocarcinoma.
Secondary therapy:
Chemotherapy